Positioned as the "value king of high-capacity fast-charging power banks," the CUKTECH 25SE perfectly addresses Malaysia's growing need for efficient and reliable power solutions. Its core strength ...
Zhou Feng, Chief Strategy Officer of Fangzhou, commented, “The collaboration represents both complementary strengths and a step toward building a new healthcare ecosystem,” adding that the company ...
Individual results vary. Dietary supplements are not substitutes for balanced nutrition, regular physical activity, or professional medical guidance. Consult a qualified healthcare provider before ...
Informational 2026 customer report evaluates ReduBurn marketing claims, ingredient transparency, thermogenic resistance framing, pricing structure, published refund terms, and consumer due diligence ...
BURLINGTON, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in five upcoming investor conferences in March.
In addition, Dr. Shaltiel will be speaking at the Advanced Therapies Congress in London in March 2026, Europe’s largest commercial cell and gene therapy conference and exhibition. The congress brings ...
NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”) will release its results for the fourth quarter and full year 2025 ended December ...
These inducement grants were granted at an exercise price per share of $0.50 and $0.57, equal to the closing price of Femasys common stock on the date of employment as reported by Nasdaq. This grant ...
XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) from The Listing Qualifications Department (the “Staff”) ...
Details for the Company’s participation are as follows: Fireside Chat: Monday, March 2, 2026 at 1:50 p.m. ET The webcast for this conference may be accessed via the “ Events ” section of the Company’s ...
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization
Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen ...
MADRID and CAMBRIDGE, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results